Abstract
The therapeutic effects of temafloxacin (TMFX) on various experimental infection models in mice were studied in comparison with those of ofloxacin (OFLX), ciprofloxacin (CPFX), norfloxacin (NFLX) and enoxacin (ENX).
1. TMFX was more effective than OFLX, CPFX, NFLX and ENX against intraperitoneal infections due to Staphylococcus aureus and streptococcal species in mice. TMFX was also superior to reference drugs against Pseudomonas aeruginosa infections. With infections due to Enterobacter aerogenes 816 and Citrobacter freundii 916, TMFX was inferior to CPFX and was equal or superior to OFLX, NFLX and ENX. The efficacies of TMFX, OFLX, ENX and NFLX in neutropenic mice were slightly reduced.
2. In experimental pneumonia caused by Klebsiella pneumoniae B-54 in mice, the therapeutic effect of TMFX was equal to those of OFLX and CPFX. However, TMFX showed a more potent therapeutic effect than OFLX, CPFX, NFLX and ENX against experimental pneumonic infections induced by Mycoplasma pulmonis m-53 in mice.
3. In ascending urinary tract infections caused by Escherichia coli 2004 in mice, the therapeutic effect of TMFX was equal to those of OFLX and CPFX. TMFX was more effective than OFLX and CPFX for kidney infections caused by Proteus mirabilis TU-1698 in carrageenan treated mice. Furthermore, the therapeutic effect of TMFX was equal to those of OFLX and CPFX in Enterococcus faecalis 1227 and Pseudomonas aeruginosa 169 infections.
4. In intestinal tract infections caused by Salmonella typhimurium TPRL-10781 in mice, the therapeutic effect of TMFX was equal or superior to that of OFLX and was superior to those of CPFX, ENX and NFLX.
5. In a subcutaneous abscess model caused by Staphylococcus aureus Y-14 (MRSA) and S.aureus CH-91 in mice, the suppressive effect of TMFX was equal to that of OFLX.
